Dxd (Exatecan derivative) |
| Catalog No.GC32926 |
Dxd (Exatecan derivative) (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1599440-33-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DXd is a derivative of Exatecan (DX-8951) [1,2,3]. DXd is a potent DNA topoisomerase I (TOP1) inhibitor with an IC50 of 0.31 µM [1].
DXd was used as the conjugated drug for DS-8201a, which is a new HER2-targeting antibody-drug conjugates (ADC ) composed of a humanized anti-HER2 antibody, enzymatically cleavable peptide-linker, and a novel topoisomerase I inhibitor [1]. Remarkable inhibitory activity to the cell growth was observed for DS-8201a against HER2-positive KPL-4, NCI-N87, and SK-BR-3, with the IC50 values of 26.8, 25.4, and 6.7 ng/mL, respectively [1]. DS-8201a clearly showed more potent antitumor efficacy, indicating 99% Tumor growth inhibition (TGI) at the dose of 4 mg/kg in HER2-positive NCI-N87 xenograft model [1].
DXd is a part structure of DS-1062a which is a trophoblast cell surface protein 2 (TROP2)-targeting antibody-drug conjugate (ADC) comprised of a humanized anti-TROP2 monoclonal antibody, enzymatically cleavable peptide-linker, and DXd [2].
DXd is an important part structure of DS-7300a, a novel B7-H3-targeting ADC, using DXd-ADC technology, which is composed of a humanized anti-B7-H3 mAb, an enzymatically cleavable tetra-peptide-based linker, and a potent TOP1 inhibitor, DXd [3].
References:
[1]. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Preclinical Efficacy of DS-8201a, a Novel HER2-Targeting ADC[J]. Clinical Cancer Research, 2016, 22(20): 5097-5108.
[2]. Okajima D, Yasuda S, Yokouchi Y, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd[J]. 2018.
[3]. Yamato M, Hasegawa J, Maejima T, et al. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-based Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Activities in Preclinical Models[J]. Molecular Cancer Therapeutics, 2022.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *